(IN BRIEF) Researchers at Newcastle University have discovered a new biological mechanism explaining why some patients do not respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. They identified T regulatory cells (Tregs) as key drivers of ICB … Read the full press release →
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged anti-CD30, Brentuximab Vedotin, Cancer Immunotherapy, cancer research, combination treatment, ICB resistance, immune checkpoint blockade, immunotherapy breakthroughs, lung cancer, melanoma, metastatic cancer, Newcastle University, pancreatic cancer, PD-1, skin cancer, solid tumors, T regulatory cells